Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug:142:104851.
doi: 10.1016/j.drugpo.2025.104851. Epub 2025 May 22.

Identifying and responding to policy-related barriers, facilitators, and misunderstandings in the HEALing communities study: A community-driven approach

Anita Silwal  1 , Robert Bohler  2 , Timothy Hunt  3 , Ramona G Olvera  4 , Michelle R Lofwall  5 , Christopher D Cook  6 , Katherine R Marks  7 , Carly Bridden  8 , Patricia R Freeman  9 , Monica Nouvong  8 , Laura C Fanucchi  10 , Nabila El-Bassel  3 , Lisa A Frazier  11 , Sharon L Walsh  5 , Jeffery C Talbert  12
Affiliations

Identifying and responding to policy-related barriers, facilitators, and misunderstandings in the HEALing communities study: A community-driven approach

Anita Silwal et al. Int J Drug Policy. 2025 Aug.

Abstract

Introduction: The HEALing (Helping to End Addiction Long-Term®) Communities Study (HCS) aimed to reduce opioid-involved overdose deaths across four states (Kentucky, Massachusetts, New York, and Ohio) via community-engaged implementation of three evidence-based practices (EBPs): (1) opioid overdose education and naloxone distribution, (2) medication for opioid use disorder expansion/linkage/retention, and (3) safer opioid prescribing and dispensing practices. A policy workgroup (PWG) was convened and developed a procedure to identify and address policies potentially impacting EBP implementation.

Methods: A five-step method was developed to identify, track, and respond to relevant policies at three of the research sites (Kentucky, Massachusetts, and New York) in collaboration with community partners and stakeholders. Policies possibly impacting EBPs were reported, reviewed, and documented, including any actions taken to address the policy issue. Policies were discussed with local, state, and federal level stakeholders in attempts to resolve barriers, clarify misunderstandings, and disseminate facilitators.

Results: A total of 87 (Kentucky = 37; Massachusetts = 19; New York = 31) policies were identified and addressed; 42 were identified as barriers, 24 as facilitators, and 21 as misunderstandings. PWG efforts resolved over 73 % (n = 31) of policy barriers, clarified 90 % (n = 19) of policy misunderstandings, and disseminated 100 % (n = 24) of policy facilitators.

Conclusions: A community-driven approach in policy surveillance identified, addressed, and disseminated several different types of policy issues that could impact implementation of EBPs for opioid-involved overdose prevention. Many policy barriers persisted during the HCS study, which may have adversely affected study outcomes.

Keywords: HEALing communities study; Medication for opioid use disorder; Opioid education and naloxone distribution; Opioid use disorder; Policy.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Michelle R. Lofwall reports research consulting in the last three years for Braeburn Pharmaceuticals, Journey Colab, and Berkshire Biomedical. Sharon Walsh reports scientific consulting in the last three years for Braeburn Pharmaceuticals, Titan, Cerevel Therapeutics, Astra Zeneca, Kinoxis, Lundbeck, Opiant, Pocket Naloxone, and Reacx. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Similar articles

See all similar articles

References

    1. Abraham AJ, Andrews CM, Harris SJ, Westlake MM, & Grogan CM (2022). Coverage and prior authorization policies for medications for opioid use disorder in Medicaid managed care. JAMA Health Forum, 3(11), e224001. 10.1001/jamahealthforum.2022.4001 - DOI - PMC - PubMed
    1. Auty SG, & Griffith KN (2022). Medicaid expansion and drug overdose mortality during the COVID-19 pandemic in the United States. Drug and Alcohol Dependence, 232, 109340. 10.1016/j.drugalcdep.2022.109340 - DOI - PMC - PubMed
    1. Bandara SN, McGinty EE, & Barry CL (2020). Message framing to reduce stigma and increase support for policies to improve the wellbeing of people with prior drug convictions. The International Journal of Drug Policy, 76, 102643. 10.1016/j.drugpo.2019.102643 - DOI - PMC - PubMed
    1. Barry CL, Sherman SG, & McGinty EE (2018). Language matters in combatting the opioid epidemic: Safe consumption sites versus overdose prevention sites. American Journal of Public Health, 108(9), 1157–1159. 10.2105/ajph.2018.304588 - DOI - PMC - PubMed
    1. Bertram RM, Blase KA, & Fixsen DL (2014). Improving programs and outcomes. Research on Social Work Practice, 25(4), 477–487. 10.1177/1049731514537687 - DOI

MeSH terms

LinkOut - more resources